MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$61,569K
Free Cash flow
$56,124K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Depreciation of fixed assets and...
Sales of available-for-sale inve...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Accounts receivable, net
Release of valuation allowance o...
Repayment of revolving credit fa...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
4,653
2,916
1,637
5,432
Goodwill impairment
-
-
0
0
Indefinite-lived intangible asset impairment
-
-
0
25,866
Release of valuation allowance on deferred tax assets
6,397
-
-
-
Investment impairment
0
-
0
0
Loss on lease terminations
-
-
0
-
Deferred taxes
3,914
1,730
-3,744
10,221
Depreciation of fixed assets and amortization of intangible assets
21,295
21,331
21,342
21,191
Amortization of debt issuance costs
-
-
-
626
Amortization of debt discount
-
-
-
56
Amortization of debt issuance costs and debt discount
577
577
2,997
-
Loss (gain) on early extinguishment of debt
-
-
0
-983
Amortization of cloud computing arrangements
663
-
-
-
Stock-based compensation
14,958
13,539
13,499
13,978
Changes in contingent consideration
1,663
-2,277
232
625
Net accretion of discount on available-for-sale investments
357
570
4,927
-
Other net gains
0
0
367
0
Accounts receivable, net
10,507
1,567
8,799
897
Inventories, net
-5,960
-2,491
-4,817
9,513
Prepaid expenses and other assets
-4,915
4,537
-12,699
-4,724
Accounts payable
3,184
-936
-2,929
-12,013
Accrued expenses
11,868
-3,160
-
7,530
Accrued expenses and other liabilities
-
-
6,853
-
Other liabilities
1,071
-1,791
-
-5,826
Net cash provided by operating activities
57,460
25,680
43,689
60,834
Acquisition of gq bio therapeutics gmbh (net of cash acquired)
0
335
0
0
Purchases of fixed assets
1,336
2,724
218
3,870
Purchases of available-for-sale investments
3,905
0
27,591
38,765
Sales of available-for-sale investments
17,000
22,500
47,142
86,249
Purchase of convertible notes receivable investment
0
-
0
0
Net cash provided by investing activities
11,759
19,441
19,333
43,614
Proceeds from exercises of stock options
457
2
490
12
Proceeds from shares issued under employee stock purchase plan
1,722
-
1,232
0
Payment of employee withholding taxes on restricted stock unit vests
3,493
4,355
143
8
Purchase of treasury stock, inclusive of broker fees
0
50,045
48,248
50,041
Proceeds from revolving credit facility
-
-
0
101,000
Proceeds from 2029 convertible senior notes
-
-
0
0
Proceeds from term loan a facility
-
-
0
-
Repayments of convertible senior notes-Convertible Senior Notes Due2024
-
-
0
0
Repayments of convertible senior notes-Convertible Senior Notes Due2025
-
-
0
202,487
Repayment of term loan facility-Term Loan BFacility
-
-
0
-
Excise taxes paid on treasury stock repurchases
1,336
-
-
-
Repayment of term loan facility-Term Loan AFacility
-
-
0
98,749
Repayment of term loan a facility
0
0
-
-
Repayment of revolving credit facility
5,000
5,000
5,000
5,000
Purchase of capped call transactions
-
-
0
0
Debt extinguishment costs
-
-
0
-
Payment of debt issuance and financing costs
-
-
-17
2,203
Net cash used in financing activities
-7,650
-59,398
-51,652
-257,476
Effect of exchange rate changes on cash and cash equivalents
0
38
-414
133
Net increase in cash and cash equivalents
61,569
-14,239
10,956
-152,895
Cash and cash equivalents, beginning of period
144,306
158,545
147,589
276,774
Cash and cash equivalents, end of period
205,875
144,306
158,545
147,589
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Depreciation of fixed assets
and amortization of...
$21,295K
(-56.08%↓ Y/Y)
Stock-based compensation
$14,958K
(-50.18%↓ Y/Y)
Accrued expenses
$11,868K
(180.87%↑ Y/Y)
Inventories, net
-$5,960K
(-126.06%↓ Y/Y)
Prepaid expenses and
other assets
-$4,915K
(-126.38%↓ Y/Y)
Sales of
available-for-sale investments
$17,000K
(-87.89%↓ Y/Y)
Net income (loss)
$4,653K
(13394.29%↑ Y/Y)
Deferred taxes
$3,914K
(82.13%↑ Y/Y)
Accounts payable
$3,184K
(-65.92%↓ Y/Y)
Changes in contingent
consideration
$1,663K
(154.85%↑ Y/Y)
Other liabilities
$1,071K
(-90.18%↓ Y/Y)
Amortization of cloud
computing arrangements
$663K
Amortization of debt issuance
costs and debt...
$577K
Net cash provided by
operating activities
$57,460K
(21.04%↑ Y/Y)
Net cash provided by
investing activities
$11,759K
(-67.81%↓ Y/Y)
Canceled cashflow
$17,261K
Canceled cashflow
$5,241K
Net increase in cash
and cash...
$61,569K
(159.68%↑ Y/Y)
Canceled cashflow
$7,650K
Accounts receivable, net
$10,507K
(904.49%↑ Y/Y)
Release of valuation
allowance on deferred tax...
$6,397K
Net accretion of
discount on...
$357K
Purchases of
available-for-sale investments
$3,905K
(-94.77%↓ Y/Y)
Purchases of fixed assets
$1,336K
(-88.12%↓ Y/Y)
Proceeds from shares
issued under employee...
$1,722K
(9.75%↑ Y/Y)
Proceeds from exercises
of stock options
$457K
Net cash used in
financing activities
-$7,650K
(87.36%↑ Y/Y)
Canceled cashflow
$2,179K
Repayment of revolving
credit facility
$5,000K
Payment of employee
withholding taxes on...
$3,493K
(-36.10%↓ Y/Y)
Excise taxes paid on
treasury stock...
$1,336K
Buy us a coffee
Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. (PCRX)